Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

78.78USD
11:38am EDT
Price Change (% chg)

$-1.94 (-2.40%)
Prev Close
$80.72
Open
$80.68
Day's High
$81.08
Day's Low
$78.52
Volume
148,210
Avg. Vol
578,582
52-wk High
$89.96
52-wk Low
$38.44

VRTX.OQ

Chart for VRTX.OQ

About

Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases. The Company’s two products are INCIVEK (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus (HCV),... (more)

Overall

Beta: 0.39
Market Cap (Mil.): $18,741.33
Shares Outstanding (Mil.): 232.18
Dividend: --
Yield (%): --

Financials

  VRTX.OQ Industry Sector
P/E (TTM): -- 44.65 37.87
EPS (TTM): -2.31 -- --
ROI: -24.14 -2.30 18.70
ROE: -42.25 -2.12 19.53
Search Stocks

Vertex loss narrows as cystic fibrosis drug sales grow

- Vertex Pharmaceuticals Inc on Monday posted a narrower quarterly loss on stronger-than-expected demand for its cystic fibrosis treatment, and it raised its full-year forecast for sales of the medicine.

29 Jul 2013

UPDATE 3-Vertex loss narrows as cystic fibrosis drug sales grow

July 29 - Vertex Pharmaceuticals Inc on Monday posted a narrower quarterly loss on stronger-than-expected demand for its cystic fibrosis treatment, and it raised its full-year forecast for sales of the medicine.

29 Jul 2013

Vertex loss narrows as demand for cystic fibrosis drug strong

July 29 - Vertex Pharmaceuticals Inc, which last week had an experimental oral hepatitis drug placed on partial clinical hold by U.S. health regulators, posted a narrower quarterly loss on stronger-than-expected demand for its cystic fibrosis treatment.

29 Jul 2013

CORRECTED-UPDATE 1-U.S. FDA puts hold on Vertex hepatitis study

(Corrects third paragraph to show hold on U.S. trial, not European study)

25 Jul 2013

CORRECTED-FDA puts hold on Vertex oral hepatitis drug trial and shares fall

(Corrects third paragraph to show hold on U.S. trial, not European study)

25 Jul 2013

Gilead profit rises, shares jump on Vertex hepatitis setback

- Shares of biotechnology company Gilead Sciences Inc jumped more than 5 percent late Thursday after rival Vertex Pharmaceuticals Inc announced a setback in development of its experimental hepatitis C drug.

25 Jul 2013

UPDATE 2-Gilead profit rises, shares jump on Vertex hepatitis setback

* Gilead is biggest maker of branded drugs to treat HIV (Adds company and analyst comments, updates share price)

25 Jul 2013

Vertex posts loss, raises cystic fibrosis sales view

- Vertex Pharmaceuticals Inc on Tuesday increased by $20 million the 2013 forecast for sales of its cystic fibrosis drug Kalydeco, and said it anticipates seeking approval in 2014 of a CF combination therapy that has become a focus for investors.

30 Apr 2013

UPDATE 3-Vertex posts loss, raises cystic fibrosis sales view

April 30 - Vertex Pharmaceuticals Inc on Tuesday increased by $20 million the 2013 forecast for sales of its cystic fibrosis drug Kalydeco, and said it anticipates seeking approval in 2014 of a CF combination therapy that has become a focus for investors.

30 Apr 2013

Vertex posts quarterly loss as hepatitis C drug sales fall

April 30 - Vertex Pharmaceuticals Inc on Tuesday reported a fourth successive quarterly loss as sales of its hepatitis C drug, Incivek, continued to plunge, but the biotechnology company raised its forecast for sales of a cystic fibrosis drug that has become the focus for investors.

30 Apr 2013

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$58.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$495.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks